Benitec Biopharma (BNTC) Projected to Post Earnings on Monday

Benitec Biopharma (NASDAQ:BNTC) is anticipated to release its earnings data on Monday, February 10th. Analysts expect Benitec Biopharma to post earnings of ($0.55) per share for the quarter.

Benitec Biopharma Price Performance

Shares of NASDAQ:BNTC opened at $11.49 on Monday. The business has a 50-day moving average of $11.18 and a two-hundred day moving average of $10.11. The firm has a market capitalization of $266.75 million, a PE ratio of -2.77 and a beta of 0.82. Benitec Biopharma has a 12 month low of $2.70 and a 12 month high of $13.29.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BNTC. Robert W. Baird initiated coverage on shares of Benitec Biopharma in a research report on Friday, December 13th. They set an “outperform” rating and a $30.00 price target on the stock. Piper Sandler restated an “overweight” rating on shares of Benitec Biopharma in a report on Friday, October 18th. JMP Securities upped their price target on shares of Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a research report on Monday, October 14th. Oppenheimer started coverage on Benitec Biopharma in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $35.00 price objective on the stock. Finally, Guggenheim reaffirmed a “buy” rating and issued a $17.00 target price on shares of Benitec Biopharma in a research report on Tuesday, December 3rd. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $24.43.

Insider Buying and Selling

In related news, Director Suvretta Capital Management, L purchased 27,502 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $10.98 per share, with a total value of $301,971.96. Following the completion of the acquisition, the director now directly owns 7,981,725 shares of the company’s stock, valued at approximately $87,639,340.50. The trade was a 0.35 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.30% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.